# A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

> **NCT07367529** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 465 (estimated)

## Conditions studied

- Advanced Lung Cancer

## Interventions

- **DRUG:** TQB6411 for Injection

## Key facts

- **NCT ID:** NCT07367529
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 465 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07367529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07367529, "A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07367529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*